Importance of genetic screens in precision oncology

被引：8

作者：

Mulero-Sanchez, Antonio ^{[1
]}

Pogacar, Ziva ^{[1
]}

Vecchione, Loredana ^{[2
]}

机构：

[1] Netherlands Canc Inst, Oncode Inst, Div Mol Carcinogenesis, Amsterdam, Netherlands

[2] Charite Univ Med Berlin, Charite Comprehens Canc Ctr, Berlin, Germany

来源：

ESMO OPEN | 2019年 / 4卷 / 03期

关键词：

METASTATIC COLORECTAL-CANCER; SYNTHETIC LETHALITY; TRASTUZUMAB RESISTANCE; PIK3CA MUTATIONS; MEK INHIBITION; PHASE IB; BRAF; CELLS; VEMURAFENIB; ACTIVATION;

D O I：

10.1136/esmoopen-2019-000505

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

Precision oncology aims to distinguish which patients are eligible for a specific treatment in order to achieve the best possible outcome. In the last few years, genetic screens have shown their potential to find the new targets and drug combinations as well as predictive biomarkers for response and/or resistance to cancer treatment. In this review, we outline how precision oncology is changing over time and describe the different applications of genetic screens. Finally, we present some practical examples that describe the utility and the limitations of genetic screens in precision oncology.

引用

页数：10

共 96 条

[51] Predicting Cancer-Specific Vulnerability via Data-Driven Detection of Synthetic Lethality [J].

Jerby-Arnon, Livnat ;

Pfetzer, Nadja ;

Waldman, Yedael Y. ;

McGarry, Lynn ;

James, Daniel ;

Shanks, Emma ;

Seashore-Ludlow, Brinton ;

Weinstock, Adam ;

Geiger, Tamar ;

Clemons, Paul A. ;

Gottlieb, Eyal ;

Ruppin, Eytan .

CELL, 2014, 158 (05) :1199-1209

[52] Functional genomics platform for pooled screening and generation of mammalian genetic interaction maps [J].

Kampmann, Martin ;

Bassik, Michael C. ;

Weissman, Jonathan S. .

NATURE PROTOCOLS, 2014, 9 (08) :1825-1847

[53] The BATTLE Trial: Personalizing Therapy for Lung Cancer [J].

Kim, Edward S. ;

Herbst, Roy S. ;

Wistuba, Ignacio I. ;

Lee, J. Jack ;

Blumenschein, George R., Jr. ;

Tsao, Anne ;

Stewart, David J. ;

Hicks, Marshall E. ;

Erasmus, Jeremy, Jr. ;

Gupta, Sanjay ;

Alden, Christine M. ;

Liu, Suyu ;

Tang, Ximing ;

Khuri, Fadlo R. ;

Tran, Hai T. ;

Johnson, Bruce E. ;

Heymach, John V. ;

Mao, Li ;

Fossella, Frank ;

Kies, Merrill S. ;

Papadimitrakopoulou, Vassiliki ;

Davis, Suzanne E. ;

Lippman, Scott M. ;

Hong, Waun K. .

CANCER DISCOVERY, 2011, 1 (01) :44-53

[54] Genome-scale transcriptional activation by an engineered CRISPR-Cas9 complex [J].

Konermann, Silvana ;

Brigham, Mark D. ;

Trevino, Alexandro E. ;

Joung, Julia ;

Abudayyeh, Omar O. ;

Barcena, Clea ;

Hsu, Patrick D. ;

Habib, Naomi ;

Gootenberg, Jonathan S. ;

Nishimasu, Hiroshi ;

Nureki, Osamu ;

Zhang, Feng .

NATURE, 2015, 517 (7536) :583-U332

[55] Updated results of the BEACON CRC safety lead-in: Encorafenib (ENCO) plus binimetinib (BIM) plus cetuximab (CETUX) for BRAFV600E-mutant metastatic colorectal cancer (mCRC). [J].

Kopetz, Scott ;

Grothey, Axel ;

Yaeger, Rona ;

Cuyle, Pieter-Jan A. R. ;

Huijberts, Sanne ;

Schellens, Jan H. M. ;

Elez, Elena ;

Fakih, Marwan ;

Viladot, Clara Montagut ;

Peeters, Marc ;

Desai, Jayesh ;

Yoshino, Takayuki ;

Ciardiello, Fortunato ;

Wasan, Harpreet Singh ;

Maharry, Kati ;

Christy-Bittel, Janna ;

Gollerkeri, Ashwin ;

Van Cutsem, Eric ;

Tabernero, Josep .

JOURNAL OF CLINICAL ONCOLOGY, 2019, 37 (04)

[56] Randomized trial of irinotecan and cetuximab with or without vemurafenib in BRAF-mutant metastatic colorectal cancer (SWOG S1406). [J].

Kopetz, Scott ;

McDonough, Shannon L. ;

Lenz, Heinz -Josef ;

Magliocco, Anthony Martin ;

Atreya, Chloe Evelyn ;

Diaz, Luis A. ;

Allegra, Carmen Joseph ;

Raghav, Kanwal Pratap Singh ;

Morris, Van Karlyle ;

Wang, Stephen E. ;

Lieu, Christopher Hanyoung ;

Guthrie, Katherine A. ;

Hochster, Howard S. .

JOURNAL OF CLINICAL ONCOLOGY, 2017, 35

[57] Phase II Pilot Study of Vemurafenib in Patients With Metastatic BRAF-Mutated Colorectal Cancer [J].

Kopetz, Scott ;

Desai, Jayesh ;

Chan, Emily ;

Hecht, Joel Randolph ;

O'Dwyer, Peter J. ;

Maru, Dipen ;

Van Morris ;

Janku, Filip ;

Dasari, Arvind ;

Chung, Woonbook ;

Issa, Jean-Pierre J. ;

Gibbs, Peter ;

James, Brian ;

Powis, Garth ;

Nolop, Keith B. ;

Bhattacharya, Suman ;

Saltz, Leonard .

JOURNAL OF CLINICAL ONCOLOGY, 2015, 33 (34) :4032-4038

[58] Molecularly targeted therapy based on tumour molecular profiling versus conventional therapy for advanced cancer (SHIVA): a multicentre, open-label, proof-of-concept, randomised, controlled phase 2 trial [J].

Le Tourneau, Christophe ;

Delord, Jean-Pierre ;

Goncalves, Anthony ;

Gavoille, Celine ;

Dubot, Coraline ;

Isambert, Nicolas ;

Campone, Mario ;

Tredan, Olivier ;

Massiani, Marie-Ange ;

Mauborgne, Cecile ;

Armanet, Sebastien ;

Servant, Nicolas ;

Bieche, Ivan ;

Bernard, Virginie ;

Gentien, David ;

Jezequel, Pascal ;

Attignon, Valery ;

Boyault, Sandrine ;

Vincent-Salomon, Anne ;

Servois, Vincent ;

Sablin, Marie-Paule ;

Kamal, Maud ;

Paoletti, Xavier .

LANCET ONCOLOGY, 2015, 16 (13) :1324-1334

[59]

Loibl S, 2004, GYNECOL ONCOL, V93, P301

[60] PIK3CA Mutations Are Associated With Lower Rates of Pathologic Complete Response to Anti-Human Epidermal Growth Factor Receptor 2 (HER2) Therapy in Primary HER2-Overexpressing Breast Cancer [J].

Loibl, Sibylle ;

von Minckwitz, Gunter ;

Schneeweiss, Andreas ;

Paepke, Stefan ;

Lehmann, Annika ;

Rezai, Mahdi ;

Zahm, Dirk M. ;

Sinn, Peter ;

Khandan, Fariba ;

Eidtmann, Holger ;

Dohnal, Karel ;

Heinrichs, Clemens ;

Huober, Jens ;

Pfitzner, Berit ;

Fasching, Peter A. ;

Andre, Fabrice ;

Lindner, Judith L. ;

Sotiriou, Christos ;

Dykgers, August ;

Guo, Sanxing ;

Gade, Stephan ;

Nekljudova, Valentina ;

Loi, Sherene ;

Untch, Michael ;

Denkert, Carsten .

JOURNAL OF CLINICAL ONCOLOGY, 2014, 32 (29) :3212-3220

← 1 2 3 4 5 6 7 8 9 10 →